- Home
- KUKE vs SKYE Comparison
KUKE vs SKYE Comparison
Compare KUKE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- SKYE
- Stock Information
- Founded
- KUKE 2002
- SKYE 2012
- Country
- KUKE China
- SKYE United States
- Employees
- KUKE N/A
- SKYE N/A
- Industry
- KUKE Other Consumer Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- SKYE Health Care
- Exchange
- KUKE Nasdaq
- SKYE Nasdaq
- Market Cap
- KUKE N/A
- SKYE 80.7M
- IPO Year
- KUKE 2021
- SKYE N/A
- Fundamental
- Price
- KUKE $4.51
- SKYE $1.79
- Analyst Decision
- KUKE
- SKYE Buy
- Analyst Count
- KUKE 0
- SKYE 6
- Target Price
- KUKE N/A
- SKYE $16.60
- AVG Volume (30 Days)
- KUKE 11.7K
- SKYE 1.7M
- Earning Date
- KUKE 05-20-2025
- SKYE 05-08-2025
- Dividend Yield
- KUKE N/A
- SKYE N/A
- EPS Growth
- KUKE N/A
- SKYE N/A
- EPS
- KUKE N/A
- SKYE N/A
- Revenue
- KUKE $14,784,158.00
- SKYE N/A
- Revenue This Year
- KUKE N/A
- SKYE N/A
- Revenue Next Year
- KUKE N/A
- SKYE N/A
- P/E Ratio
- KUKE N/A
- SKYE N/A
- Revenue Growth
- KUKE 10.48
- SKYE N/A
- 52 Week Low
- KUKE $0.15
- SKYE $1.14
- 52 Week High
- KUKE $4.58
- SKYE $13.49
- Technical
- Relative Strength Index (RSI)
- KUKE 71.80
- SKYE 47.86
- Support Level
- KUKE $4.05
- SKYE $1.36
- Resistance Level
- KUKE $4.55
- SKYE $2.30
- Average True Range (ATR)
- KUKE 0.29
- SKYE 0.20
- MACD
- KUKE -0.06
- SKYE 0.03
- Stochastic Oscillator
- KUKE 90.00
- SKYE 45.74
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.